For Immediate Release
Chicago, IL – November 5, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Nucor Corporation NUE, Dow Inc. DOW, Pfizer Inc. PFE, Costco Wholesale Corporation COST and Lowe’s Companies Inc. LOW.
Here are highlights from Thursday’s Analyst Blog:
Fed Chair Speaks in Cautious Tone Despite Tapering: 5 Picks
The Federal Reserve has finally announced its much-expected tapering of the ongoing quantitative easing program. On Nov 3, Fed Chairman Jerome Powell said in his post-FOMC meeting statement that the central bank will start reducing its existing $120 billion per month bond-buy program ($80 billion Treasury Note and $40 billion mortgage-backed securities), effective this month.
Despite adopting the first major shift from the ultra-dovish monetary policies that it initiated in March 2020, the overall tone of Powell’s statement still sounds dovish as he categorically delinked bond-buy tapering from the future interest rate hike.
Fed Remains Dovish Despite Tapering
The Fed has decided to reduce its existing bond-buy program by $15 billion per month ($10 billion Treasury Note and $5 billion mortgage-backed securities) later this month. At this rate, the quantitative easing program will terminate in June 2022. The gradual elimination of the monetary stimulus is a calculated move by the central bank to avoid a 2013 like taper tantrum.
Having initiated the tapering, the Fed chair said, “Our decision today to begin tapering our asset purchases does not imply any direct signal regarding our interest rate policy. We continue to articulate a different and more stringent test for the economic conditions that would need to be met before raising the federal funds rate.”
In this regard, Powell only slightly adjusted the Fed’s view on inflation from “transitory” to “expected to be transitory.” This clearly implies that the central bank is in no hurry to hike the benchmark interest rate from the current range of 0-0.25%. He also said that the Fed is ready to adjust the pace of tapering “if warranted by changes in the economic outlook.”
Wall Street Welcomes Fed’s Decision
The Fed’s decision was mostly in line with market participants’ expectations. The central bank has injected this unprecedented monetary stimulus to maintain sufficient liquidity in the system to cope with unprecedented economic devastation owing to the coronavirus-led pandemic. The central bank has decided to gradually withdraw that stimulus as the economy has made sufficient progress.
Market valuation has already discounted the likelihood of the Fed starting to taper its monthly bond-buy program this month as the inflation rate skyrocketed to a 30-year high. Prolonged supply-chain disruptions, a labor shortage and massive pent-up demand are the primary reasons for the galloping inflation.
In fact, the dovish tone of the Fed Chair bodes well with the market. As a result, the three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — gained 0.3%, 0.7% and 1%, respectively. The small-cap-centric Russell 2000 advanced 1.8%.
The current projection by the CME FedWatch shows a 9% probability that the central bank will hike the benchmark interest rate in early 2022. The Fed has maintained that a rate hike is unlikely before the second half of 2022. Moreover, Powell’s statement also signaled that the first rate hike may be delayed till late 2022.
Moreover, not all stocks will succumb to a higher interest rate. Even if the Fed changes its current projection, pushing up the market’s interest rate earlier than expected, corporate bigwigs are unlikely to bear the brunt of a rising interest rate. These companies have a robust business model across the world and command globally acclaimed brand values. Their strong financial position will help them to cope with a higher interest rate.
Our Top Picks
Several good stocks are available for investment for the rest of this year. However, we have applied our VGM Style Score to narrow down the search to five stocks. These stocks have strong growth potential for the rest of 2021 and have seen solid earnings estimate revisions within the past 7 days, indicating that the market currently expects these companies to do solid business in 2021.
Each of our picks carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a VGM Score of A. You can see the complete list of today’s Zacks #1 Rank stocks here.
Nucor Corp. is a leading producer of structural steel, steel bars, steel joists, steel deck and cold-finished bars in the United States. It operates through three segments: Steel Mills, Steel Products, and Raw Materials.
The company has been seeing consistent momentum in the non-residential construction market. Demand in the non-residential construction markets was strong in the most recent quarter. Nucor’s downstream products unit has been benefiting from continued strength in the non-residential construction markets.
This Zacks Rank #1 company has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings improved 7.7% over the last 30 days.
Dow should gain from cost synergy savings and productivity initiatives. The company is focused on maintaining cost and operational discipline through cost synergy and stranded cost-removal initiatives. Its actions to reduce operating costs are expected to lend support to its earnings in 2021.
Dow’s restructuring program is also expected to deliver margin benefits. Investment in high-return projects should also be accretive to its earnings. Management is investing in several high-return growth projects, including the expansion of downstream silicones capacity.
This Zacks Rank #1 company has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings improved 0.3% over the last 7 days.
Pfizer expects strong growth of key brands like Ibrance, Inlyta and Eliquis to drive sales. Its COVID-19 vaccine candidate, developed in record time, is now approved for emergency use in several countries and has become a key contributor to the top line. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
Pfizer has committed a significant number of resources toward the development of treatments in the fields of oncology, internal medicine, rare diseases, immunology, inflammation, vaccines and hospital. Its phase III success rate, on a five-year rolling average, has improved from 70% to 85%.
This Zacks Rank #2 company has an expected earnings growth rate of 84.7% for the current year. The Zacks Consensus Estimate for current-year earnings improved 0.5% over the last 7 days.
Costco operates membership warehouses in the United States, Puerto Rico, Canada, the United Kingdom, Mexico, Japan, Korea, Australia, Spain, France, Iceland, China, and Taiwan. It offers branded and private-label products in a range of merchandise categories.
Its growth strategies, better price management, decent membership trend and increasing penetration of e-commerce business reinforce its position. The strategy to sell products at discounted prices has helped to draw customers seeking both value and convenience. These factors have been aiding in registering impressive sales numbers.
This Zacks Rank #2 company has an expected earnings growth rate of 7.7% for the current year (ending August 2022). The Zacks Consensus Estimate for current-year earnings has improved 0.3% over the last 7 days.
Lowe’s remains well-positioned to capitalize on the demand in the home improvement market backed by investments in technology, merchandise category and strength in Pro business. Management is committed toward expanding the company’s market share and boosting the operating margin.
The company’s new total home strategy that includes providing complete solutions for various types of home repair and improvement needs bodes well. The strategy is an extension of the company’s retail-fundamentals approach.
This Zacks Rank #2 company has an expected earnings growth rate of 27.9% for the current year (ending January 2022). The Zacks Consensus Estimate for current-year earnings has improved 0.6% over the last 30 days.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Nucor Corporation (NUE) : Free Stock Analysis Report
Lowe’s Companies, Inc. (LOW) : Free Stock Analysis Report
Dow Inc. (DOW) : Free Stock Analysis Report
Costco Wholesale Corporation (COST) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research